{
  "ticker": "TERN",
  "company_name": "TERN",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05791864",
      "title": "A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Neuronal Ceroid Lipofuscinosis Type 2",
      "start_date": "2023-05-17",
      "completion_date": "2031-07-30",
      "enrollment": 0,
      "sponsor": "Tern Therapeutics, LLC"
    }
  ],
  "summary": {
    "total_trials": 1,
    "by_phase": {
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Neuronal Ceroid Lipofuscinosis Type 2"
    ],
    "lead_stage": "unknown"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:49:16.683490",
    "search_query": "TERN",
    "url": "https://clinicaltrials.gov/search?term=TERN"
  }
}